Source comparison
Quick Comparison
Protein family: Thymosin Alpha-1 belongs to the alpha thymosin family (prothymosin alpha derivative); TB-500 belongs to the beta thymosin family (a Thymosin Beta-4 fragment). Sequence: Thymosin Alpha-1 is a 28-amino acid peptide; TB-500 is Ac-LKKTETQ, a 7-amin
This comparison does not assign a generated winner or score.
- Protein family: Thymosin Alpha-1 belongs to the alpha thymosin family (prothymosin alpha derivative); TB-500 belongs to the beta thymosin family (a Thymosin Beta-4 fragment).
- Sequence: Thymosin Alpha-1 is a 28-amino acid peptide; TB-500 is Ac-LKKTETQ, a 7-amino acid fragment.
- Molecular weight: Thymosin Alpha-1 approximately 3,108 Da; TB-500 approximately 889 Da.
- Primary mechanism: Thymosin Alpha-1 works via TLR2/7/9 activation, T-cell maturation, and cytokine modulation; TB-500 works via G-actin sequestration, cell migration, angiogenesis, and stem cell mobilization.
- Primary effect: Thymosin Alpha-1 provides immune enhancement and modulation; TB-500 drives tissue repair and systemic healing.
- Pharmaceutical name: Thymosin Alpha-1 is marketed as thymalfasin (Zadaxin); TB-500 has no pharmaceutical name — it is a research compound.
- FDA status: Thymosin Alpha-1 has Orphan Drug designation but is not fully approved; TB-500 is not approved and is prohibited by the FDA for compounding.
- International approval: Thymosin Alpha-1 is approved in over 35 countries; TB-500 is not approved in any country.
- WADA status: Thymosin Alpha-1 is not prohibited; TB-500 is explicitly prohibited under S2.3 since 2018.
- Standard dose: Thymosin Alpha-1 is 1.6 mg subcutaneous twice weekly; TB-500 is 2–2.5 mg subcutaneous twice weekly during the loading phase.
- Key clinical evidence: Thymosin Alpha-1 has hepatitis B RCTs, meta-analyses, and cancer adjunct trials; TB-500's evidence base consists of Phase 2 trials for wound healing conducted with the parent TB4 compound.